Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

SCHOTT Assists the Pharmaceutical Industry on Tracking Pharmaceutical Tubing

Published: Thursday, January 23, 2014
Last Updated: Thursday, January 23, 2014
Bookmark and Share
Company issues its 1 millionth certificate for its FIOLAX® glass tubing.

SCHOTT is supporting the pharmaceutical industry in its efforts to track the tubing used to produce pharmaceutical packaging made of glass. The company issued its 1 millionth certificate for its FIOLAX® glass tubing just recently.

These certificates help to identify the products shipped as tubing that are subsequently processed into pharmaceutical packaging, vials or syringes, for example.

They contain more detailed information on the dimensional quality and the quality of the glass. This enables pharmaceutical companies to track their packaging all the way back to the raw material “glass tubing,” if necessary.

Traceability is currently one of the most pressing issues for the pharmaceutical industry. It is closely related to more stringent requirements for quality and safety in manufacturing, shipping and administering medicines. Packaging is thus an integral part of all safety considerations.

SCHOTT became the first company in the industry to allow for all of the pharmaceutical tubing it manufactures to be identified back in 1999. The certificates are applied to the pallet in a clearly visible position and enable customers to inspect incoming shipments more easily because they contain plenty of detailed information.

One part of the certificate can be detached and stored for documentation purposes and used to perform subsequent tracking & tracing inside the e-commerce portal.

SCHOTT’s certificates can be distinguished from the certificates that its competitors use mainly in terms of their great depth of detail and clarity. Besides a description of the product that includes an exact definition of all of the characteristics of importance to the customer, they also contain highly detailed specifications on tolerances.

“In other words, we offer our customers the highest possible transparency and reliable quality,” concludes Jürgen Achatz, Global Sales Director for Pharmaceutical Tubing at SCHOTT.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SCHOTT Launches New Center of Excellence for RTU Pharma Packaging
Initiative will more closely tie together SCHOTT’s experts and pharma partners as production of adaptiQ® ready-to-use vials commences.
Saturday, October 24, 2015
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos